Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825242 | 0.86 | TAAR1 (0.53) | SMN1; SMN2ALDH1A1GAARAB9ATAAR1 | |
| SCHEMBL4598776 | 0.83 | EPHX1 (0.56) | SMN1; SMN2ALDH1A1GAARAB9ATAAR1 | |
| SCHEMBL4826844 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1GAARAB9ATAAR1 | |
| SCHEMBL4821845 | 0.82 | TAAR1 (0.74) | SMN1; SMN2ALDH1A1GAARAB9ATAAR1 | |
| SCHEMBL4598121 | 0.81 | TAAR1 (0.54) | SMN1; SMN2ALDH1A1RAB9ATAAR1MC4R | |
| SCHEMBL3189768 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1GAARAB9ALMNA | |
| SCHEMBL4819683 | 0.80 | TAAR1 (0.63) | ALDH1A1TAAR1EPHX2 | |
| SCHEMBL4825552 | 0.79 | USP2 (0.47) | SMN1; SMN2ALDH1A1RAB9ATAAR1LMNA | |
| SCHEMBL4821449 | 0.78 | NPC1 (0.67) | SMN1; SMN2ALDH1A1RAB9ATAAR1EPHX2 | |
| SCHEMBL4597880 | 0.78 | TAAR1 (0.61) | ALDH1A1GAATAAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | SMN1; SMN2 3010/4885ALDH1A1 1616/4885GAA 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.